A major cause of resistance to azole antifungal drugs in Candida albicans is overproduction of the plasma membrane drug efflux pumps Cdr1p, Cdr2p and/or Mdr1p, but little is known about these pumps' physical and catalytic properties. It also is not known if mutations in these pumps' structural genes (CDR1, CDR2 and MDR1) cause azole resistance in clinical C. albicans strains. This project will use genetic, cell biological and biochemical approaches to pursue two specific aims.
Aim 1 is to determine if Cdr1p, Cdr2p and Mdr1p actively transport azoles across the plasma membrane and to define these proteins' properties. CDR1, CDR2 or MDR1 will be expressed in a conditional C. albicans sec4 mutant, and secretory vesicles from these cells will be tested for the ability to transport [3H]-fluconazole across their membranes. The vesicles will also be used to examine each recombinant protein's physical properties, catalytic constants, substrate specificities and inhibitor profile.
Aim 2 is to determine if mutations in the CDR1, CDR2 and/or MDR1 coding sequences cause azole resistance in C. albicans. Azole-susceptible and azole-resistant C. albicans strains from different groups of patients will be tested for [3H]-fluconazole accumulation and for CDR1, CDR2 and MDR1 overexpression. The CDR1, CDR2 and MDR1 ORFs from [3H]-fluconazole-underaccumulating strains that do not overexpress CDR1, CDR2 or MDR1 will be cloned and expressed in a C. albicans cdr1 cdr2 mdr1 null mutant. Any ORF that confers higher levels of azole resistance in the cdr1 cdr2 mdr1 mutant than does its wild-type counterpart will be sequenced, its protein product will be analyzed using isolated C. albicans secretory vesicles, and its effects on azole resistance will be verified in wild-type C. albicans transformants. The longterm goal of these studies is to develop new strategies and approaches for overcoming and/or preventing the emerging problem of azole resistance in C. albicans. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI064085-02
Application #
7218266
Study Section
Special Emphasis Panel (ZRG1-DDR (01))
Program Officer
Duncan, Rory A
Project Start
2005-05-15
Project End
2008-04-30
Budget Start
2006-04-01
Budget End
2006-04-30
Support Year
2
Fiscal Year
2005
Total Cost
$261,582
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Basso Jr, Luiz R; Gast, Charles E; Mao, Yuxin et al. (2010) Fluconazole transport into Candida albicans secretory vesicles by the membrane proteins Cdr1p, Cdr2p, and Mdr1p. Eukaryot Cell 9:960-70
Basso Jr, Luiz R; Bartiss, Ann; Mao, Yuxin et al. (2010) Transformation of Candida albicans with a synthetic hygromycin B resistance gene. Yeast 27:1039-48
Mao, Yuxin; Zhang, Zimei; Gast, Charles et al. (2008) C-terminal signals regulate targeting of glycosylphosphatidylinositol-anchored proteins to the cell wall or plasma membrane in Candida albicans. Eukaryot Cell 7:1906-15
Lee, Samuel A; Jones, Jason; Khalique, Zachary et al. (2007) A functional analysis of the Candida albicans homolog of Saccharomyces cerevisiae VPS4. FEMS Yeast Res 7:973-85